Stafia-1

CAS No. 2582757-90-0

Stafia-1( —— )

Catalog No. M28612 CAS No. 2582757-90-0

Stafia-1 is a potent STAT5a inhibitor ( IC50=22.2 μM). Stafia-1 displays high selectivity over STAT5b and other STAT family members.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 177 Get Quote
10MG 293 Get Quote
25MG 498 Get Quote
50MG 716 Get Quote
100MG 981 Get Quote
500MG 1998 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Stafia-1
  • Note
    Research use only, not for human use.
  • Brief Description
    Stafia-1 is a potent STAT5a inhibitor ( IC50=22.2 μM). Stafia-1 displays high selectivity over STAT5b and other STAT family members.
  • Description
    Stafia-1 is a potent STAT5a inhibitor ( IC50=22.2 μM). Stafia-1 displays high selectivity over STAT5b and other STAT family members.
  • In Vitro
    Stafia-1 shows at least 9-fold selectivity over STAT5b and higher selectivity against other STAT family members.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    JAK/STAT Signaling
  • Target
    STAT
  • Recptor
    NOP receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2582757-90-0
  • Formula Weight
    506.44
  • Molecular Formula
    C24H27O10P
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 250 mg/mL (493.64 mM)
  • SMILES
    COC1=CC(C2=CC(OP(O)(O)=O)=CC(C3=CC(OC)=C(OC)C(OC)=C3)=C2)=CC(OC)=C1OC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Thomsen C, Hohlweg R. (8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triaza-spiro[4. 5]dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist. Br J Pharmacol. 2000 Nov;131(5):903-8.
molnova catalog
related products
  • CAY10784

    CAY10784 (STAT3-IN-17) is a STAT3 inhibitor with antiproliferative and antitumor activities. CAY10784 showed antibacterial activity against Clostridium difficile.

  • MMPP

    MMPP is a novel VEGFR2 inhibitor with anti-inflammatory and potential anticancer activity, inhibits STAT3, inhibits angiogenesis via VEGFR2/AKT/ERK/NF-kappaB pathway, and can be used to alleviate myocardial injury.

  • ML116

    A novel selective STAT3 inhibitor with IC50 of 4.2 uM.